Form 4: Galera Therapeutics CEO Sells Shares Under 10b5-1 Plan

Galera Therapeutics' President and CEO, J. Mel Sorensen, sold 70,000 shares of common stock on November 20, 2025, under a Rule 10b5-1 plan.

Summary

• J. Mel Sorensen, President and CEO of Galera Therapeutics, Inc., reported a sale of common stock.
• The transaction involved 70,000 shares of common stock.
• The shares were sold on November 20, 2025, at a weighted average price of $0.0201 per share.
• The sale was executed pursuant to a Rule 10b5-1 trading plan, which provides an affirmative defense against insider trading allegations.
• Following the transaction, Sorensen beneficially owns 195,029 shares of common stock.

Sentiment

Score: 4

Explanation: The sale of shares by the President and CEO, even under a pre-arranged Rule 10b5-1 plan, can be viewed with slight caution by investors, particularly given the low share price.

Positives

• The transaction was conducted under a Rule 10b5-1 plan, indicating a pre-scheduled sale and enhancing transparency regarding insider trading.

Negatives

• The President and CEO sold a significant number of shares (70,000), which can be perceived negatively by investors, especially given the very low share price of $0.0201.

Related Party Transactions

• J. Mel Sorensen, President and CEO, sold 70,000 shares of Galera Therapeutics, Inc. common stock on November 20, 2025, at a weighted average price of $0.0201 per share.

Stakeholder Impact

• Shareholders may perceive the insider sale as a negative signal, potentially impacting investor confidence, although the use of a Rule 10b5-1 plan mitigates some concerns regarding opportunistic trading.

Key Dates

Keywords

Galera Therapeutics, GRTX, Mel Sorensen, insider trading, stock sale, Form 4, CEO, common stock, 10b5-1 plan